– UK, London – Silence Therapeutics plc (LON: SLN / Nasdaq: SLN), a global clinical-stage company developing novel siRNA therapies, announced the appointment of Tim McInerney to its Board of Directors, effective immediately.
“We are thrilled to welcome Tim to the Silence Board,” said Board Chairman, Iain Ross. “Tim is a seasoned executive and board member with extensive experience in both the investment and pharmaceutical industries. We look forward to his guidance as we continue our evolution towards the U.S. markets while positioning Silence as a global siRNA leader.”
The company also announced that James Ede-Golightly will retire from the Board at the AGM in June 2025,
About Tim McInerney
Tim McInerney brings over 30 years of experience as a pharmaceutical executive and healthcare investment banker/analyst with positions in industry and several Wall Street firms. Following positions at Bristol Myers, Bear Stearns, and Ladenburg Thalmann, Tim oversaw the overall distribution of Paramount Biocapital’s private equity product and was directly responsible for capital raised for both startups and private placement investments in the healthcare sector. In the early-stage financings of Cougar Biotech (acquired by J&J), Kite Pharma (acquired by Gilead), Velcera (acquired by Perrigo), and Ziopharm Oncology, Tim played a significant role. He has served on numerous public and private boards, including as chairman of Insite Vision (acquired by Sun Pharmaceuticals) and Edgemont Pharmaceuticals (acquired by Alvogen Inc.). He also served on the board of Emisphere Technologies and chaired the Special Committee in negotiating its sale to Novo Nordisk for $1.8 billion in December 2020. In addition, Tim is a co-founding investor and board member of Corino Therapeutics. His decades of board experience also include serving on audit, compensation, and governance committees.
Tim McInerney received his B.S. in Pharmacy from St. John’s University and also completed a postgraduate residency in drug information systems at the New York University Medical Center.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need, with programs advancing in cardiovascular disease, hematology, and rare diseases.
For more: https://www.silence-therapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.